RxDoctor Payments Data

Jonathan Hines, MD

Internal Medicine · Wilmington, NCNPI 1619066040

Payments from drug & device makers

$1,060in general payments, 2019–2025

Across 55 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tosoh Bioscience, Inc.$226
  • Novo Nordisk$175
  • AstraZeneca$98
  • Ferring Pharmaceuticals Inc.$83
  • Boehringer Ingelheim$76
  • Amarin Pharma, Inc.$67
  • plus $336 from 16 others

What the payments were for

  • Food & beverage$83479%
  • Gifts$22621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,060 in reported general payments places this provider in the 75th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$282,759
Medicare patients
739
Services billed
12,167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$123,790
EliquisApixaban113$104,796
XareltoRivaroxaban39$43,709
FarxigaDapagliflozin Propanediol17$23,457
MounjaroTirzepatide16$22,287
JanuviaSitagliptin Phosphate31$20,419
JardianceEmpagliflozin23$18,066
TrulicityDulaglutide12$15,443
MyrbetriqMirabegron23$10,100
Atorvastatin Calcium782$9,595
SymbicortBudesonide/Formoterol Fumarate12$8,220
Novolog FlexpenInsulin Aspart24$8,032
PremarinEstrogens, Conjugated15$6,840
Breo ElliptaFluticasone/Vilanterol12$5,194
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$4,453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$175$123,79090 claims
PfizerEliquis, Premarin$12$111,637128 claims
Johnson & JohnsonXarelto$35$43,70939 claims
Lilly USA, LLCMounjaro, Trulicity$40$37,73028 claims
AstraZenecaFarxiga, Symbicort$98$31,67729 claims
Boehringer IngelheimJardiance$76$18,06623 claims
GSKBreo Ellipta$26$5,19412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →